Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 22,012 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Major Depression Disorder
Interventions: Spravato, IV Ketamine; Drug
Lead sponsor: Yale University; Other
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 8
States / cities: Milford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 5 more

Conditions: Sentinel Lymph Node
Interventions: ICG Intervention, Near Infrared Imaging; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity and Obesity-related Medical Conditions, Diabetes, Atherosclerotic Disease, Heart Failure, MASH, Sarcopenia, Osteoporosis, Hyperparathyroidism, Hypoparathyroidism, Ischemic Heart Disease, Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Osteopenia, Cachexia
Interventions: Endothelial cell collection; Other
Lead sponsor: Bettina Mittendorfer; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Colo-rectal Cancer
Interventions: Cemiplimab, cemiplimab plus fianlimab, cemiplimab + REGN7075, ctDNA testing; Drug · Other
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Gainesville, Florida • Iowa City, Iowa • Kansas City, Kansas + 9 more

Conditions: Acute Spinal Cord Injury
Interventions: GlyBURIDE Oral Tablet; Drug
Lead sponsor: Francis Farhadi; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Body Composition
Interventions: EmeraldLED; Device
Lead sponsor: Efforia, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Infantile Spasm
Interventions: Fenfluramine; Drug
Lead sponsor: Children's Hospital of Orange County; Other
Eligibility: 12 Months to 36 Months
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Los Angeles, California • Orange, California

Conditions: Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma
Interventions: MGC028; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: San Francisco, California • Boston, Massachusetts • Grand Rapids, Michigan + 3 more

Conditions: Cardiovascular Diseases, Obesity
Interventions: Wait-List Control, PREVENT Tool; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Concussions
Interventions: COmmunities Aligned to reduce Concussion and Head impact exposure (COACH) Intervention; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 11 Years to 14 Years
Enrollment: 880 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognition Disorders in Old Age, Cognitive Decline, Cognitive Deterioration
Interventions: Combination of 40Hz light and cognitive therapy (ALZLIFE); Device
Lead sponsor: Alzheimer's Light LLC; Industry
Eligibility: 50 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Balance Assessment, Falls, Plantar Sensation
Interventions: None AHT; Other
Lead sponsor: RxFunction Inc.; Industry
Eligibility: 20 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Kidney Stones, Urinary Stone Disease / Nephrolithiasis, Recurrent Calcium-oxalate Kidney Stones
Interventions: Microbial Transplant Therapy (FMT CAPSULE DE / FMPCapDE / MTP-CP101), Vancomycin and neomycin antibiotic pretreatment; Drug
Lead sponsor: Joshua Stern; Other
Eligibility: 18 Years to 69 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Park City, Utah

Conditions: RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
Interventions: PAS-004 Capsules, PAS-004 Tablets; Drug
Lead sponsor: Pasithea Therapeutics Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas • Fairfax, Virginia

Conditions: Type 1 Diabetes
Interventions: blood draw; Other
Lead sponsor: University of Florida; Other
Eligibility: 0 Years to 100 Years
Enrollment: 2,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2085
U.S. locations: 3
States / cities: Gainesville, Florida • Columbus, Ohio • Houston, Texas

Conditions: RSV
Interventions: zelicapavir, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Cape Coral, Florida • Miami, Florida • Bluffton, South Carolina + 1 more

Conditions: Graft-versus-host Disease
Interventions: Cyclophosphamide, Abatacept, Bortezomib; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 14 Years to 100 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Head and Neck Cancer, Survivorship, Caregiver Burden, Head and Neck Neoplasms
Interventions: Survivorship Needs Assessment Planning (SNAP) tool; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions: OBP-301, Pembrolizumab; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin, Melanoma in Situ, Carcinoma in Situ of Skin, Hemangioma, Melanocytic Nevi, Other Benign Neoplasms of Skin, Neoplasm of Uncertain Behavior of Skin, Neoplasm of Uncertain Behavior, Unspecified, Neoplasm of Unspecified Behavior of Bone, Soft Tissue, and Skin, Nevus, Non-Neoplastic, Skin Changes Due to Chronic Exposure to Nonionizing Radiation, Other Specified Follicular Disorders, Other Melanin Hyperpigmentation, Seborrheic Keratosis, Congenital Non-Neoplastic Naevus
Interventions: Clinical decision support tool; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Stanford, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Chronic Pancreatitis
Interventions: EUS-guided celiac plexus block, Sham procedure; Procedure
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias, Early Stage Lower Genital Tract Cancers
Interventions: Diagnostic tests for anal cancer screening; Diagnostic Test
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 35 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: New York, New York • Charleston, South Carolina • Houston, Texas

Conditions: Traumatic Brain Injury, Intracerebral Haemorrhage, Subarachnoid Haemorrhagic Stroke
Interventions: Auditory stimuli; Diagnostic Test
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 2
States / cities: Miami, Florida • New York, New York

Conditions: Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma, B-Cell Lymphoproliferative Disorder, Indolent Lymphoma
Interventions: Pacritinib; Drug
Lead sponsor: Shayna Sarosiek, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

The OBSERVE Protocol

Bronchial NIR Image-guided Resection

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

Spinal Cord Injury Neuroprotection With Glyburide

Can EmeraldLED Reshape Your Body With Continued Use?

Treatment of Refractory Infantile Spasms With Fenfluramine

A Study of MGC028 in Participants With Advanced Solid Tumors

Evaluation of a Novel Technology to Support Tailored Health Behavior Counseling in Rural Primary Care Clinics

COmmunities Aligned to Reduce Concussion and Head Impact Exposure

Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy

How's Your Balance?

Fecal Microbiota Transplantation in Kidney Stone Patients

PAS-004 in Patients With Advanced Solid Tumors

Immune Function and the Progression to T1D

A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease

Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)

The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis

EUS-guided Celiac Plexus Block vs. Sham in Chronic Pancreatitis

Screening Women With Prior HPV for Anal Neoplasia

The EBC Recovery Study

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia